Encoded Therapeutics is a pioneering brand that specializes in genetic medicines and the development of innovative gene therapy solutions. They are focused on addressing pediatric central nervous system (CNS) diseases and providing effective treatments for patients and their families. With a strong team of experts in gene therapy development, Encoded Therapeutics is dedicated to creating a viable and sustainable gene therapy innovation engine.

Their products and services encompass a wide range of areas, including clinical studies, research, and publications. One of their notable programs is ETX101, which is aimed at treating Dravet Syndrome. Encoded Therapeutics also places a strong emphasis on building a supportive patient community, with stories and resources available for those affected by Dravet Syndrome.

The brand is led by a team of experienced professionals who bring a depth of expertise in gene therapy development. Their leadership spans from concept to commercialization, ensuring that Encoded Therapeutics remains at the forefront of cutting-edge treatments. With a focus on innovation and expertise, Encoded Therapeutics is committed to revolutionizing gene therapy and improving the lives of patients with CNS diseases